Personalized DAPT Benefit Risk Decision Tool
Clinical risk assessment
Select the clinician-assessed risk categories and whether long-term oral anticoagulation is indicated.
Clinical context
This tool supports a structured discussion of antithrombotic therapy after acute coronary syndrome (ACS). It does not calculate an individualized net clinical benefit, and the category labels are clinician-entered descriptors rather than validated scores.
For ACS patients who are not at high bleeding risk, the 2025 ACC/AHA ACS guideline recommends aspirin plus an oral P2Y12 inhibitor for at least 12 months as the default. Selected patients may use bleeding-reduction strategies, including ticagrelor monotherapy after at least 1 month of tolerated DAPT, or single antiplatelet therapy after 1 month in selected high-bleeding-risk patients.
Practical checks before choosing a strategy
- Confirm the ACS presentation, management strategy, date of PCI, and current antithrombotic regimen.
- Assess bleeding risk with a structured method where appropriate, and do not equate a subjective “high” label automatically with ARC-HBR.
- Review stent and procedural complexity, prior MI or stent thrombosis, recurrent ischemia, anemia, renal function, frailty, tolerance, and adherence.
- If long-term oral anticoagulation is indicated, explicitly document the planned duration of triple therapy and when aspirin should be stopped.
- Consider a proton pump inhibitor when gastrointestinal bleeding risk is elevated and antithrombotic therapy is required.
References
Eur Heart J. 2019;40:2632–2653. DOI: 10.1093/eurheartj/ehz372
Eur Heart J. 2023;44:3720–3826. DOI: 10.1093/eurheartj/ehad191
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.